Table 3 Characteristics of children who did and did not develop tuberculosis (TB) following co-trimoxazole randomization
At co-trimoxazole randomization | TB | No TB | Total | P value |
|---|---|---|---|---|
| Â | 20 (3Â %) | 602 (97Â %) | 622 | Â |
Randomization | ||||
 Stop co-trimoxazole | 15 (5) | 297 (95) | 312 |  |
 Continue co-trimoxazole | 5 (2) | 305 (98) | 310 | 0.024 |
Age (at co-trimoxazole randomization) | ||||
 Median, IQR | 6.5 (3.5–11.5) | 7 (4–10) |  |  |
 <5 years | 10 (3) | 280 (97) | 290 | 0.75 |
Sex | ||||
 Male | 8 (3) | 295 (97) | 303 |  |
 Female | 12 (4) | 307 (96) | 319 | 0.43 |
CD4 median IQR (time-updated) | ||||
 CD4 % | 18 (11.5–31) | 33 (26–38) |  | <0.001 |
Weight median IQR (time-updated) | ||||
 Weight-for-age Z score | −1.0 (−2.1 to –0.5) | −1.3 (1.9 to –0.6) |  | 0.60 |
Height median IQR (time-updated) | ||||
 Height-for-age Z score | −1.8 (−3.0 to –0.9) | −1.9 (−2.7 to –1.1) |  | 0.92 |
WHO stage (pre-ART) | ||||
 3 and 4 | 13 (3) | 378 (97) | 391 | 0.84 |
ART randomization | ||||
 A (3TC/ABC/NNRTI throughout) | 8 (4) | 192 (96) | 200 |  |
 B (3TC/ABC/NNRTI post week 36) | 8 (4) | 210 (96) | 218 |  |
 C (3TC/ABC/ZDV post week 36) | 4 (2) | 200 (98) | 204 | 0.46 |
ART at co-trimoxazole randomization | ||||
 3TC ABC EFV | 4 (3) | 134 (97) | 138 |  |
 3TC ABC NVP | 11 (4) | 245 (96) | 256 |  |
 ZDV 3TC ABC | 4 (2) | 196 (98) | 200 |  |
 Other | 1 (4) | 27 (96) | 28 | 0.58 |